| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 08/04/2023 | 244.33% | Goldman Sachs | $27 → $24 | Maintains | Buy |
| 05/05/2023 | 301.72% | Credit Suisse | $34 → $28 | Maintains | Outperform |
| 02/28/2023 | — | Cowen & Co. | Initiates Coverage On | → Outperform | |
| 02/22/2023 | 359.11% | BMO Capital | $40 → $32 | Maintains | Outperform |
| 02/22/2023 | 387.8% | Credit Suisse | → $34 | Reiterates | → Outperform |
| 01/06/2023 | 158.25% | SVB Leerink | $20 → $18 | Maintains | Outperform |
| 12/15/2022 | 330.42% | Goldman Sachs | → $30 | Initiates Coverage On | → Buy |
| 11/16/2022 | 316.07% | Truist Securities | → $29 | Initiates Coverage On | → Buy |
| 11/09/2022 | 186.94% | SVB Leerink | $13 → $20 | Maintains | Outperform |
| 08/10/2022 | 387.8% | Credit Suisse | $40 → $34 | Maintains | Outperform |
| 07/26/2022 | 215.64% | Piper Sandler | $21 → $22 | Maintains | Overweight |
| 05/11/2022 | 201.29% | Piper Sandler | $28 → $21 | Maintains | Overweight |
| 05/11/2022 | 100.86% | SVB Leerink | $20 → $14 | Maintains | Outperform |
| 02/25/2022 | 473.89% | Credit Suisse | $39 → $40 | Maintains | Outperform |
| 02/25/2022 | 186.94% | SVB Leerink | $25 → $20 | Maintains | Outperform |
| 12/21/2021 | 287.37% | Benchmark | → $27 | Initiates Coverage On | → Buy |
| 11/19/2021 | 373.46% | Piper Sandler | → $33 | Initiates Coverage On | → Overweight |
| 08/13/2021 | 603.01% | Credit Suisse | $51 → $49 | Maintains | Outperform |
| 05/14/2021 | 631.71% | Credit Suisse | $53 → $51 | Maintains | Outperform |
| 03/30/2021 | 689.1% | Stifel | $59 → $55 | Maintains | Buy |
| 02/08/2021 | 646.05% | SVB Leerink | $45 → $52 | Maintains | Outperform |
| 01/05/2021 | 660.4% | Berenberg | → $53 | Initiates Coverage On | → Buy |
| 01/05/2021 | 545.62% | SVB Leerink | → $45 | Initiates Coverage On | → Outperform |
| 01/05/2021 | — | Credit Suisse | Initiates Coverage On | → Outperform | |
| 01/05/2021 | 746.48% | Stifel | → $59 | Initiates Coverage On | → Buy |
| 01/05/2021 | 588.67% | BMO Capital | → $48 | Initiates Coverage On | → Outperform |
What is the target price for AbCellera Biologics (ABCL)?
The latest price target for AbCellera Biologics (NASDAQ: ABCL) was reported by Goldman Sachs on August 4, 2023. The analyst firm set a price target for $24.00 expecting ABCL to rise to within 12 months (a possible 244.33% upside). 10 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for AbCellera Biologics (ABCL)?
The latest analyst rating for AbCellera Biologics (NASDAQ: ABCL) was provided by Goldman Sachs, and AbCellera Biologics maintained their buy rating.
When is the next analyst rating going to be posted or updated for AbCellera Biologics (ABCL)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of AbCellera Biologics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for AbCellera Biologics was filed on August 4, 2023 so you should expect the next rating to be made available sometime around August 4, 2024.
Is the Analyst Rating AbCellera Biologics (ABCL) correct?
While ratings are subjective and will change, the latest AbCellera Biologics (ABCL) rating was a maintained with a price target of $27.00 to $24.00. The current price AbCellera Biologics (ABCL) is trading at is $6.97, which is out of the analyst's predicted range.